Spectral AI, Inc. (MDAI), Monday announced the submission of De Novo 510k marketing clearance application to the U.S. Food and Drug Administration for the DeepView System.
The system is a non-invasive, predictive medical device and associated software platform that combines multispectral imaging with a proprietary AI algorithm to assess the healing potential of burn wounds.
The system is expected to help clinicians with an immediate, data-driven assessment tool designed to assist clinical decision-making and may significantly improve patient outcomes.
In the pre-market hours, Spectral's stock is trading at $2.18, up 2.8 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.